Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Importance: There is limited evidence on the benefits of sacubitril/valsartan vs broader renin angiotensin system inhibitor background therapy on surrogate outcome markers, 6-minute walk distance, and quality of life in patients with heart failure and mildly reduced or preserved left ventricular ejection fraction (LVEF >40%). Objective: To evaluate the effect of sacubitril/valsartan on N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, 6-minute walk distance, and quality of life vs background medication-based individualized comparators in patients with chronic heart failure and LVEF of more than 40%. Design, Setting, and Participants: A 24-week, randomized, double-blind, parallel group clinical trial (August 2017-October 2019). Of 4632 patients screened at 396 centers in 32 countries, 2572 patients with heart failure, LVEF of more than 40%, elevated NT-proBNP levels, structural heart disease, and reduced quality of life were enrolled (last follow-up, October 28, 2019). Interventions: Patients were randomized 1:1 either to sacubitril/valsartan (n = 1286) or to background medication-based individualized comparator (n = 1286), ie, enalapril, valsartan, or placebo stratified by prior use of a renin angiotensin system inhibitor. Main Outcomes and Measures: Primary end points were change from baseline in plasma NT-proBNP level at week 12 and in the 6-minute walk distance at week 24. Secondary end points were change from baseline in quality of life measures and New York Heart Association (NYHA) class at 24 weeks. Results: Among 2572 randomized patients (mean age, 72.6 years [SD, 8.5 years]; 1301 women [50.7%]), 2240 (87.1%) completed the trial. At baseline, the median NT-proBNP levels were 786 pg/mL in the sacubitril/valsartan group and 760 pg/mL in the comparator group. After 12 weeks, patients in the sacubitril/valsartan group (adjusted geometric mean ratio to baseline, 0.82 pg/mL) had a significantly greater reduction in NT-proBNP levels than did those in the comparator group (adjusted geometric mean ratio to baseline, 0.98 pg/mL) with an adjusted geometric mean ratio of 0.84 (95% CI, 0.80 to 0.88; P < .001). At week 24, there was no significant between-group difference in median change from baseline in the 6-minute walk distance with an increase of 9.7 m vs 12.2 m (adjusted mean difference, -2.5 m; 95% CI, -8.5 to 3.5; P = .42). There was no significant between-group difference in the mean change in the Kansas City Cardiomyopathy Questionnaire clinical summary score (12.3 vs 11.8; mean difference, 0.52; 95% CI, -0.93 to 1.97) or improvement in NYHA class (23.6% vs 24.0% of patients; adjusted odds ratio, 0.98; 95% CI, 0.81 to 1.18). The most frequent adverse events in the sacubitril/valsartan group vs the comparator group were hypotension (14.1% vs 5.5%), albuminuria (12.3% vs 7.6%), and hyperkalemia (11.6% vs 10.9%). Conclusions and Relevance: Among patients with heart failure and left ventricular ejection factor of higher than 40%, sacubitril/valsartan treatment compared with standard renin angiotensin system inhibitor treatment or placebo resulted in a significantly greater decrease in plasma N-terminal pro-brain natriuretic peptide levels at 12 weeks but did not significantly improve 6-minute walk distance at 24 weeks. Further research is warranted to evaluate potential clinical benefits of sacubitril/valsartan in these patients. Trial Registration: ClinicalTrials.gov Identifier: NCT03066804.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957
Self-citationCardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206
Yusuf, S., Pfeffer, M. A., Swedberg, K., Granger, C. B., Held, P., McMurray, J. J., Michelson, E. L., Olofsson, B., & Östergren, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14285-7 · Cited by 2,994
Spironolactone for heart failure with preserved ejection fraction
Pitt, B., Pfeffer, M. A., Assmann, S. F., Boineau, R., Anand, I. S., Claggett, B., Clausell, N., Desai, A. S., Diaz, R., Fleg, J. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313731 · Cited by 2,809
Self-citationAngiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
Solomon, S. D., McMurray, J. J. V., Anand, I. S., Ge, J., Lam, C. S. P., Maggioni, A. P., Martinez, F., Packer, M., Pfeffer, M. A., Pieske, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908655 · Cited by 2,430
Self-citationGroenewegen, A., Rutten, F. H., Mosterd, A., & Hoes, A. W. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1858 · Cited by 2,043
Irbesartan in patients with heart failure and preserved ejection fraction
Massie, B. M., Carson, P. E., McMurray, J. J., Komajda, M., McKelvie, R., Zile, M. R., Anderson, S., Donovan, M., Iverson, E., Staiger, C., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805450 · Cited by 1,960
Phenomapping for Novel Classification of Heart Failure With Preserved Ejection Fraction
Shah, S. J., Katz, D. H., Selvaraj, S., Burke, M. A., Yancy, C. W., Gheorghiade, M., Bonow, R. O., Huang, C.-C., & Deo, R. C. (2015) · Circulation · doi:10.1161/circulationaha.114.010637 · Cited by 1,157
Self-citationSacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure
Solomon, S. D., Vaduganathan, M., L. Claggett, B., Packer, M., Zile, M., Swedberg, K., Rouleau, J., A. Pfeffer, M., Desai, A., H. Lund, L., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.044586 · Cited by 551
Self-citationA graphical approach to sequentially rejective multiple test procedures
Bretz, F., Maurer, W., Brannath, W., & Posch, M. (2009) · Statistics in Medicine · doi:10.1002/sim.3495 · Cited by 420
Cited by
Heart Failure With Preserved Ejection Fraction
Borlaug, B. A., Sharma, K., Shah, S. J., & Ho, J. E. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.01.049 · Cited by 742
Self-citationHeart Failure With Preserved Ejection Fraction: A Review
Redfield, M. M., & Borlaug, B. A. (2023) · JAMA · doi:10.1001/jama.2023.2020 · Cited by 662
Kosiborod, M. N., Bhatt, A. S., Claggett, B. L., Vaduganathan, M., Kulac, I. J., Lam, C. S. P., Hernandez, A. F., Martinez, F. A., Inzucchi, S. E., Shah, S. J., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.11.006 · Cited by 86
Self-citationAlbuminuria as a marker of systemic congestion in patients with heart failure
Boorsma, E. M., ter Maaten, J. M., Damman, K., van Essen, B. J., Zannad, F., van Veldhuisen, D. J., Samani, N. J., Dickstein, K., Metra, M., Filippatos, G., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehac528 · Cited by 70
McMurray, J. J. V., Docherty, K. F., de Boer, R. A., Hammarstedt, A., Kitzman, D. W., Kosiborod, M. N., Maria Langkilde, A., Reicher, B., Senni, M., Shah, S. J., et al. (2024) · Circulation · doi:10.1161/circulationaha.123.065061 · Cited by 60
Self-citation
Metadata
- Authors
- Pieske, B., Wachter, R., Shah, S. J., Baldridge, A., Szeczoedy, P., Ibram, G., Shi, V., Zhao, Z., Cowie, M. R., PARALLAX Investigators and Committee members, Prado, A. C., Wenetz, L. M. M., Brasca, D. G., Albisu, J. P., Fernandez, A. A., Liberman, A., Echeverria, G., Bartolacci, I., Ranz, M., Pedrotti, M., Tapia, D., Robertson, M., Exposito, S., Barrionuevo, M., Resk, J. H., Mercau, G., Fuente, R. L. D. L., Avaca, H., Poy, C., Hominal, M. A., Cursack, G., Vogelmann, O. A., Casas, M. M., Costantino, M., Chiriffe, J., Zweiker, R., Motloch, L. J., Auer, J., Siostrzonek, P., Grander, W., Derthoo, D., Mullens, W., Vandekerckhove, H., Maamar, R., Delforge, M., Mulleners, T., Rassi, S., Kormann, A. P. M., Moraes, A., Manenti, E. R. F., Reis, G., Maia, L. N., Simoes, M. V., Silva, R. P., Danzmann, L. C., Saraiva, J. F. K., Sternieri, M. C. V. B. B., de Souza, W. S. B., Figueiredo, E. L., Tzekova, M. L., Boeva, B., Vasilev, D., Gospodinova, S. T. T., Milanova, M. H., Kabakchieva, V. M., Valchanova, P. I., Dimov, B., Petrovsky, P., Georgiev, P. G., Spasova, N., Mazhdrakov, G., Konteva, M., Benov, H. O., Denchev, S. V., Parent, M., Demers, C., Dion, D., Bourgeois, R. L., Heffernan, M. L., Silgado, G. A. M., Quiroz, F., Cadena, A., Mendoza, J. L. A., Saldarriaga, C., Arana, C., Nechvatal, L., Linhartova, K., Klimsa, Z., Busak, L., Marek, D., Slaby, J., Polasek, R., Koleckar, P., Carda, J., Kaislerova, M., Trestik, P., Zajicek, P., Kuchar, J., Vondrak, J., Krupicka, J., Brychta, T., Lang, P., Rickers, H., Hove, J. D., Gustafsson, I., Nielsen, O. W., Uuetoa, T., Noodla, S., Rosenthal, A., Vettus, R., Fauchier, L., Aboyans, V., DUTOIU, T. M., Decoulx, E., Geeter, G. D., Khanoyan, P., Donal, E., Rosamel, Y., Berthelot, E., Seronde, M.-F., Winkelmann, B. R., Grosskopf, W., Haas, J., Schmitt, B., Jahnke, N., Wilke, A., Simonis, G., Bosiljanoff, P., Proskynitopoulos, N., Axthelm, C., Schenkenberger, I., Proepper, F., Frey, N., Edelmann, F., Fechtrup, C., Graf, T., Seidel, M., Fehske, W., Prohaska, M., Unsoeld, B., Birner, C., Jungmair, W., Hoelscher, A., Kadel, C., Lahiri, K., Mehling, H., Hagenow, A., Naudts, I. F. K., Winkler, J., Salbach, P., Naumann, R., Killat, H., Bastian, D., Baeumer, A. T., Goldmann, B., Cuneo, A., Hoepfner, F., Noutsias, M., Beermann, J., Rieker, W., Buckert, D., Woehrle, J., Westphal, J., Bekfani, T., Stoerk, S., Schnupp, S., Stoehring, R., Neumann, T., Knapp, M., Bourgeois, J., Edel, K., Sarnighausen, H.-E., Nitschke, T., Jeserich, M., Ebelt, H., Linke, A., Gaub, R., Sueselbeck, T., Stratmann, M., Toursarkissian, N., Steinebach, I., Krackhardt, F., Schueler, R., Brandt, M., Placke, J., Stangl, V., Schoebel, C., Tschoepe, D., Overhoff, U., Stenzel, G., Stellbrink, C., Schwefer, M., Lorenz, E., Uebel, P., Gluesing, D., Weissbrodt, M., John, F., Arango, J. L., Castellanos, J. M., Chang, C., Haase, F., Lopez, E. M., Ovando, A., Paniagua, V., Vogel, M., Estrada, M. A. R., Rodriguez, I., Corona, V., Takacs, J., Varga, A., Nyolczas, N., Kalina, A., Nagy, A. C., Merkely, B., Mehta, A., Chopada, M. B., Ghaisas, N. K., Sethi, R., Basavanna, D., Devasia, T., Agarwal, D. K., Bhalani, N. C., Shah, U. G., Chanana, B. B., Washimkar, S. N., Bental, T., Goland, S., Azzam, Z., Weinstein, J. M., Magen, E., Gal, T. B., Fucili, A., Pedretti, R. F. E., Servi, S. D., Baronio, B., Gronda, E., Barbagallo, M., Margonato, A., Cosmi, F., Giannattasio, C., Pavan, D., Mazza, A., Ramazzina, E., Senni, M., Inserra, C. A., Argiolas, G., Borghi, C., Sime, I., Veze, I., Mora, L., Pontaga, N., Plisiene, J., Celutkiene, J., Cepinskiene, L., Leon, J. L. A., Leon, S., Padilla, F., Cerda, R. C., Linssen, G., Jansen, A., Hermans, W., Bellersen, L., Meer, P. V. D., Lok, D. J. A., Olimulder, M., Hal, J. M. C. V., Troquay, R., de Bie, M., Heerebeek, L. V., Flores, R. M. C., Camacho, D. L. A., Rodriguez, A., Alarco, W., Lu, L. I., Osores, J. J. A. L., Cabrera, W., Gaspar, A., Martins, J., Sarmento, P., Fonseca, C., Brito, D., Marques, I., Leao, S., Nascimento, A., Andrade, A., Nica, N. C., Ciobotaru, G. V., Coman, S. I., Copaci, I., Dumitrascu, A., Iosipescu, L., Jurcut, R., Militaru, C., Podoleanu, C., Stanciulescu, G., Tomescu, M. C., Tudoran, M., Voicu, O. C., Giuca, A., Mercea, C. D., Teodorescu, I., Shvarts, Y. G., Gapon, L. I., Izmozherova, N. V., Khaisheva, L. A., Nosov, V. P., Mozheiko, M. E., Shutemova, E. A., Privalov, D. V., Baglikov, A., Kastanayan, A. A., Kobalava, Z., Koziolova, N. A., Zotov, D. D., Lipchenko, A., Burova, N. N., Polezhaeva, N., Pavlova, I., Ermoshkina, L. G., Zrazhevsky, K. N., Boldueva, S. A., Akatova, E. V., Martsevich, S. Y., Apostolovic, S., Boskovic, S., Davidovic, G., Deljanin-Ilic, M., Ilic, A., Dzupina, A., Fulop, P., Jesensky, T., Nociar, J., Predmerska, A., Schichorova, J., Sokolova, B., Lukacova, J., Smik, R., Stofkova, D., Kolikova, V., Papincak, J., Sabo, L., Urgeova, L., Macek, V., Klabnik, A., Letavay, P., Prochazka, L., Vinanska, D., Majercak, I., Dominguez, A. T., Pinilla, J. M. G., Lama, M. G., Villota, J. N., Bonet, L. A., Freire, J. R. B., Perez, G. P., Figal, D. P., Diz, F. W., Quintana, A. G., Fernandez, J. D., Cerezo, J. G., Encinar, J. B., Delgado, F. G., Iborra, P. L., Jurad, F. J. C., Seller, J., Kiatchoosakun, S., Chirakarnjanakorn, S., Sansanayudh, N., Srimahachota, S., Thongsri, T., Mahavanakul, W., Sahin, T., Yigit, Z., Melek, M., Akin, M., Cavusoglu, Y., Koc, M., Ozcan, I. T., Turgut, O. O., Yilmaz, M. B., Altay, H., Muderrisoglu, H., Badak, O., Tekten, T., Oguzhan, A., Kucuk, M., Mahmood, S., Dewhurst, M. J., Asamoah-Owusu, N., Clifford, P., Takhar, A., Hayes, C., Moriarty, A., Witte, K., Cooke, J., Haas, D., Portnay, E., Feitell, S., Brown, C. S., Hattler, B., Fail, P., Haddad, T., Rama, B., Kapoor, N., Aslam, S., Peters, M., Sanchez, E., Vijayasekaran, S., Lupovitch, S. D., Jonsson, O., Schmalfuss, C., Jain, A., Mentzer, G., Lepor, N., Mignone, J., Drummond, W., Soverow, J., Gaggin, H., Garver, R. I., Martinez-Castrillon, M., Jaffrani, N., Harris, B. D., Bernstein, M., Sizemore, B. C., Wells, T., Schwartz, A. C., Alhaddad, M., White, A., Dargie, H., Komajda, M., Foley, R., Francis, G., Pocock, S., Kaplan, A. P., Brown, N., Zuraw, B., & Busse, P. J.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2021-11-16
- Volume
- 326
- Issue
- 19
- Pages
- 1919
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W3211446055
- Cited by
- 163
- References
- 12
- FWCI
- 16.19
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial. https://app.cochat.ai/papers/10.1001/jama.2021.18463
- The paper
- Pieske, B., Wachter, R., Shah, S. J., Baldridge, A., Szeczoedy, P., Ibram, G., Shi, V., Zhao, Z., Cowie, M. R., PARALLAX Investigators and Committee members, Prado, A. C., Wenetz, L. M. M., Brasca, D. G., Albisu, J. P., Fernandez, A. A., Liberman, A., Echeverria, G., Bartolacci, I., Ranz, M., . . . Busse, P. J. (2021). Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial. JAMA. https://doi.org/10.1001/jama.2021.18463
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.